Similar to CD45, AIS is only significantly associated with improved outcomes in patients who received trastuzumab-based adjuvant chemotherapy (HR 0.66, 95% CI 0.49–0.90, Cox regression model p = 0.01), but not in patients who received chemotherapy alone (HR 0.96, 95% CI 0.67–1.40, Cox regression model p = 0.97, Fig. 3). The gene discussed is PTPRC; the disease is androgen insensitivity syndrome.